In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.
The FDA has until Monday to decide whether to approve the first new Alzheimer's drug in nearly two decades. Two big studies of the drug produced conflicting results.